Prediction of clinical toxicity in locally advanced head and neck cancer patients by radio-induced apoptosis in peripheral blood lymphocytes (PBLs)

Radiation Oncology

Volumn 5, Issue 1, 2010, Pages

  Bordón, Elisa ^a   Henríquez Hernández, Luis A ^a,b   Lara, Pedro C ^a,c   Ruíz, Ana ^c   Pinar, Beatriz ^a,c   Rodríguez Gallego, Carlos ^a,c   Lloret, Marta ^a,c  

^a Madrid Spain   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; CD45 ANTIGEN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PROPIDIUM IODIDE;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CELL ISOLATION; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGUS DISEASE; FEMALE; FLOW CYTOMETRY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; LARYNX DISORDER; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PREDICTION; RADIATION DOSE; RADIATION INJURY; SKIN TOXICITY; TOXICITY TESTING; XEROSTOMIA; CELL SEPARATION; HEAD AND NECK TUMOR; KAPLAN MEIER METHOD; LYMPHOCYTE; MIDDLE AGED; MORTALITY; RADIATION EXPOSURE; RADIOTHERAPY;

ADULT; AGED; APOPTOSIS; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOCYTES; MALE; MIDDLE AGED; RADIATION TOLERANCE; RADIOTHERAPY; XEROSTOMIA; YOUNG ADULT;

EID: 77249109445     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-5-4     Document Type: Article

References (22)

1. Dawood S, Leyland-Jones B. Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest 2009, 27:482-488. 10.1080/07357900802574660, 19479485.
2. Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. Int J Radiat Oncol Biol Phys 2000, 48:745-750.
3. Fernet M, Hall J. Predictive markers for normal tissue reactions: fantasy or reality?. Cancer Radiother 2008, 12:614-618.
4. Buchholz TA. Finding our sensitive patients. Int J Radiat Oncol Biol Phys 1999, 45:547-548.
5. Hennequin C, Quero L, Favaudon V. [Determinants and predictive factors of tumour radiosensitivity]. Cancer Radiother 2008, 12:3-13.
6. Henriquez Hernandez LA, Lara PC, Pinar B, Bordon E, Rodriguez Gallego C, Bilbao C, Fernandez Perez L, Flores Morales A. Constitutive gene expression profile segregates toxicity in locally advanced breast cancer patients treated with high-dose hyperfractionated radical radiotherapy. Radiat Oncol 2009, 4:17. 10.1186/1748-717X-4-17, 2698866, 19497124.
7. Rodningen OK, Borresen-Dale AL, Alsner J, Hastie T, Overgaard J. Radiation-induced gene expression in human subcutaneous fibroblasts is predictive of radiation-induced fibrosis. Radiother Oncol 2008, 86:314-320. 10.1016/j.radonc.2007.09.013, 17963910.
8. Langendijk JA, Doornaert P, Rietveld DH, Verdonck-de Leeuw IM, Leemans CR, Slotman BJ. A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol 2009, 90:189-195. 10.1016/j.radonc.2008.12.017, 19167120.
9. Crompton NE, Miralbell R, Rutz HP, Ersoy F, Sanal O, Wellmann D, Bieri S, Coucke PA, Emery GC, Shi YQ, Blattmann H, Ozsahin M. Altered apoptotic profiles in irradiated patients with increased toxicity. Int J Radiat Oncol Biol Phys 1999, 45:707-714.
10. Barber JB, West CM, Kiltie AE, Roberts SA, Scott D. Detection of individual differences in radiation-induced apoptosis of peripheral blood lymphocytes in normal individuals, ataxia telangiectasia homozygotes and heterozygotes, and breast cancer patients after radiotherapy. Radiat Res 2000, 153:570-578. 10.1667/0033-7587(2000)153[0570:DOIDIR]2.0.CO;2, 10790278.
11. Bordon E, Henriquez Hernandez LA, Lara PC, Pinar B, Fontes F, Rodriguez Gallego C, Lloret M. Prediction of clinical toxicity in localized cervical carcinoma by radio-induced apoptosis study in peripheral blood lymphocytes (PBLs). Radiat Oncol 2009, 4:58. 10.1186/1748-717X-4-58, 2787528, 19941649.
12. Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, Sozzi WJ, Zouhair A, Mirimanoff RO, Azria D. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res 2005, 11:7426-7433. 10.1158/1078-0432.CCR-04-2634, 16243816.
13. Crompton NE, Ozsahin M, Schweizer P, Larsson B, Luetolf UM. Theory and practice of predictive assays in radiation therapy. Strahlenther Onkol 1997, 173:58-67. 10.1007/BF03038924, 9048972.
14. Crompton NE, Shi YQ, Emery GC, Wisser L, Blattmann H, Maier A, Li L, Schindler D, Ozsahin H, Ozsahin M. Sources of variation in patient response to radiation treatment. Int J Radiat Oncol Biol Phys 2001, 49:547-554. 10.1016/S0360-3016(00)01477-2, 11173153.
15. Ozsahin M, Ozsahin H, Shi Y, Larsson B, Wurgler FE, Crompton NE. Rapid assay of intrinsic radiosensitivity based on apoptosis in human CD4 and CD8 T-lymphocytes. Int J Radiat Oncol Biol Phys 1997, 38:429-440.
16. Schmitz A, Bayer J, Dechamps N, Thomas G. Intrinsic susceptibility to radiation-induced apoptosis of human lymphocyte subpopulations. Int J Radiat Oncol Biol Phys 2003, 57:769-778.
17. Huguenin PU, Taussky D, Moe K, Meister A, Baumert B, Lutolf UM, Glanzmann C. Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: the importance of the target volume. Int J Radiat Oncol Biol Phys 1999, 45:47-52.
18. Munter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, Nill S, Wannenmacher M, Debus J. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 2004, 58:175-184. 10.1016/S0360-3016(03)01437-8, 14697436.
19. Winczura P, Jassem J. Combined treatment with cytoprotective agents and radiotherapy. Cancer Treat Rev 2009,
20. Antonadou D, Pepelassi M, Synodinou M, Puglisi M, Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002, 52:739-747. 10.1016/S0360-3016(01)02683-9, 11849797.
21. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339-3345.
22. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 2005, 63:985-990.